Fibroblast growth factor receptor 3 is a negative regulator of bone growth - PubMed (original) (raw)

Fibroblast growth factor receptor 3 is a negative regulator of bone growth

C Deng et al. Cell. 1996.

Free article

Abstract

Endochondral ossification is a major mode of bone that occurs as chondrocytes undergo proliferation, hypertrophy, cell death, and osteoblastic replacement. We have identified a role for fibroblast growth factor receptor 3 (FGFR-3) in this process by disrupting the murine Fgfr-3 gene to produce severe and progressive bone dysplasia with enhanced and prolonged endochondral bone growth. This growth is accompanied by expansion of proliferating and hypertrophic chondrocytes within the cartilaginous growth plate. Thus, FGFR-3 appears to regulate endochondral ossification by an essentially negative mechanism, limiting rather than promoting osteogenesis. In light of these mouse results, certain human disorders, such as achondroplasia, can be interpreted as gain-of-function mutations that activate the fundamentally negative growth control exerted by the FGFR-3 kinase.

PubMed Disclaimer

Similar articles

• A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors.
  Li C, Chen L, Iwata T, Kitagawa M, Fu XY, Deng CX. Li C, et al. Hum Mol Genet. 1999 Jan;8(1):35-44. doi: 10.1093/hmg/8.1.35. Hum Mol Genet. 1999. PMID: 9887329
• Restrained chondrocyte proliferation and maturation with abnormal growth plate vascularization and ossification in human FGFR-3(G380R) transgenic mice.
  Segev O, Chumakov I, Nevo Z, Givol D, Madar-Shapiro L, Sheinin Y, Weinreb M, Yayon A. Segev O, et al. Hum Mol Genet. 2000 Jan 22;9(2):249-58. doi: 10.1093/hmg/9.2.249. Hum Mol Genet. 2000. PMID: 10607835
• Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains.
  Wang Q, Green RP, Zhao G, Ornitz DM. Wang Q, et al. Development. 2001 Oct;128(19):3867-76. doi: 10.1242/dev.128.19.3867. Development. 2001. PMID: 11585811
• Recent research on the growth plate: Advances in fibroblast growth factor signaling in growth plate development and disorders.
  Xie Y, Zhou S, Chen H, Du X, Chen L. Xie Y, et al. J Mol Endocrinol. 2014 Aug;53(1):T11-34. doi: 10.1530/JME-14-0012. J Mol Endocrinol. 2014. PMID: 25114206 Review.
• Mouse models orthologous to FGFR3-related skeletal dysplasias.
  Brodie SG, Deng CX. Brodie SG, et al. Pediatr Pathol Mol Med. 2003 Jan-Feb;22(1):87-103. doi: 10.1080/pdp.22.1.87.103. Pediatr Pathol Mol Med. 2003. PMID: 12687892 Review.

Cited by

• Nutrient and Hormonal Effects on Long Bone Growth in Healthy and Obese Children: A Literature Review.
  Hasan S, Naseer S, Zamzam M, Mohilldean H, Van Wagoner C, Hasan A, Saleh ES, Uhley V, Kamel-ElSayed S. Hasan S, et al. Children (Basel). 2024 Jul 3;11(7):817. doi: 10.3390/children11070817. Children (Basel). 2024. PMID: 39062266 Free PMC article. Review.
• Stem-Cell-Driven Chondrogenesis: Perspectives on Amnion-Derived Cells.
  Sulcanese L, Prencipe G, Canciello A, Cerveró-Varona A, Perugini M, Mauro A, Russo V, Barboni B. Sulcanese L, et al. Cells. 2024 Apr 24;13(9):744. doi: 10.3390/cells13090744. Cells. 2024. PMID: 38727280 Free PMC article. Review.
• Long-term oral meclozine administration improves survival rate and spinal canal stenosis during postnatal growth in a mouse model of achondroplasia in both sexes.
  Funahashi H, Matsushita M, Esaki R, Mishima K, Ohkawara B, Kamiya Y, Takegami Y, Ohno K, Kitoh H, Imagama S. Funahashi H, et al. JBMR Plus. 2024 Feb 24;8(4):ziae018. doi: 10.1093/jbmrpl/ziae018. eCollection 2024 Apr. JBMR Plus. 2024. PMID: 38544920 Free PMC article.
• Mice Lacking PLAP-1/Asporin Show Alteration of Periodontal Ligament Structures and Acceleration of Bone Loss in Periodontitis.
  Kinoshita M, Yamada S, Sasaki J, Suzuki S, Kajikawa T, Iwayama T, Fujihara C, Imazato S, Murakami S. Kinoshita M, et al. Int J Mol Sci. 2023 Nov 5;24(21):15989. doi: 10.3390/ijms242115989. Int J Mol Sci. 2023. PMID: 37958972 Free PMC article.
• Cell-based screen identifies porphyrins as FGFR3 activity inhibitors with therapeutic potential for achondroplasia and cancer.
  Lin YW, Kao HJ, Chen WT, Kao CF, Wu JY, Chen YT, Lee YC. Lin YW, et al. JCI Insight. 2023 Nov 22;8(22):e171257. doi: 10.1172/jci.insight.171257. JCI Insight. 2023. PMID: 37824212 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations

• Molecular Biology Databases

  • BioCyc
  • Gene Ontology
  • GlyGen glycoinformatics resource
  • Mouse Genome Informatics (MGI)
  • The Weizmann Institute of Science GeneCards and MalaCards databases

• Research Materials

  • Cellosaurus - a cell line knowledge resource